Avasimibe (Synonyms: Cl-1011, PD-148515) |
| カタログ番号GC10999 |
ACAT阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 166518-60-1
Sample solution is provided at 25 µL, 10mM.
Avasimibe is an orally bioavailable inhibitor of the acyl coenzyme A: cholesterol acyltransferase (ACAT) with IC50 value of 60nM [1].
Avasimibe is developed from a strategy to design ACAT inhibitors with improved bioavailability. It also has solution stability at acidic pH. In the in vitro assay, the IC50 value is dependent on the concentration of microsomes, the amount of membrane available for adsorption as well as the presence of BSA. The treatment of avasimibe during the process of lipid loading causes a concentration-dependent reduction in cellular cholesteryl ester content. This reduction is not accompanied by the accumulation of intracellular free cholesterol, indicating a better safety profile for avasimibe than other ACAT inhibitors. Avasimibe can also reduce the synthesis and secretion of Apo B 100 (a component of VLDL) in HepG2 cells. In addition, avasimibe can increase the total bile acid synthesis in rat hepatocytes at the concentration of 3μM [1].
Apart from the antiatherosclerotic efficacy, avasimibe is also found to take participate in the modulation of APP trafficking. It can delay and reduce the maturation of APP, limiting the availability of APP holoprotein for Aβ-generatiion [2].
References:
[1] Llaverías G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). 2003 Spring;21(1):33-50.
[2] Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 2009 Nov;23(11):3819-28.
| Cell experiment [1]: | |
|
Cell lines |
HepG2 cells; rat hepatocytes; THP-1 cells |
|
Preparation method |
The solubility of this compound in DMSO is >25.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.2 μM-10 μM; 24 h |
|
Applications |
In THP-1 cells, avasimibe (0-0.2 μM) did not reduce intracellular cholesteryl ester content in a sequential incubation system. Incubations with avasimibe (0-0.2 μM) during the process of lipid loading (simultaneous incubation with avasimibe and acetyl-LDL) caused a concentration-dependent reduction in cellular cholesteryl ester content, which reached 70% at 0.2 μM. Incubation with avasimibe (10 nM - 10 μM) for 24 h caused a significant dose-dependent reduction in apo B 100 secretion from HepG2 cells. Overnight incubation of HepG2 cells with 10 μM avasimibe suppressed apo B synthesis, as well as the synthesis of other hepa-to-specific proteins. Avasimibe (3 μM) caused a 2.9-fold increase in total bile acid synthesis in rat hepatocytes. |
| Animal experiment [1]: | |
|
Animal models |
Rats, Mice |
|
Dosage form |
Oral; 1, 10, or 30 mg/kg/day; 2 weeks |
|
Application |
In mice, treatment with avasimibe significantly reduced the number of lesions containing accumulations of free cholesterol. In cholesterol-fed rats treated with multiple oral doses of the compound, avasimibe significantly reduced plasma total cholesterol and increased HDL-cholesterol. Avasimibe (0.01% in the diet for 1 week) reduced plasma cholesterol levels in rats fed a high fat-high cholesterol diet, supplemented or not with 0.5% cholate, by 52 to 71%. Treatment with avasimibe (3–30 mg/kg/day) for 8–10 weeks lowered plasma total cholesterol, VLDL-cholesterol, LDL-cholesterol, and triglyceride levels.In chow-fed rats, avasimibe (3–30 mg/kg) reduced plasma cholesterol levels by 44 to 66%. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Llaverías G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). 2003 Spring;21(1):33-50. | |
| Cas No. | 166518-60-1 | SDF | |
| 同義語 | Cl-1011, PD-148515 | ||
| Chemical Name | [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate | ||
| Canonical SMILES | CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C | ||
| Formula | C29H43NO4S | M.Wt | 501.72 |
| 溶解度 | ≥ 25.1 mg/mL in DMSO, ≥ 10.26 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9931 mL | 9.9657 mL | 19.9314 mL |
| 5 mM | 0.3986 mL | 1.9931 mL | 3.9863 mL |
| 10 mM | 0.1993 mL | 0.9966 mL | 1.9931 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *